Rhode Island is currently home to 506 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Providence, Warwick, East Providence and Johnston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Alcohol Feedback, Reflection and Morning Evaluation
NCT05509218
Recruiting
The investigators propose to examine mornings after drinking as an optimal time to provide repeated, personalized feedback, with the goal of reducing hazardous drinking. Specifically, the investigators will further develop and pilot test a novel theory-based personalized feedback intervention (PFI) for heavy drinking young adults. Intervention strategies include personalized feedback (e.g., feedback on prior night blood alcohol concentration, consequences) contrasted with both drinking goals set... Read More
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
03/27/2025
Locations: Brown University, Providence, Rhode Island
Conditions: Youth Drinking, Alcohol Drinking
Register for Updates
Pilot Neurobehavioral Therapy for Functional Neurological Disorder
NCT06873698
Recruiting
The goal of this pilot randomized clinical trial is to learn if Neurobehavioral Therapy (NBT) works to treat motor functional neurological disorder (mFND) (also referred to as functional motor disorder). The main questions it aims to answer are: * Does NBT lower mFND symptoms? * Does NBT lower common co-occurring symptoms and improve functioning? Researchers will compare NBT to standard medical care (SMC). Participants will be randomized to receive either: * 12 weekly sessions of NBT, along... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/26/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Functional Neurological Disorder
Register for Updates
Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose
NCT06316830
Recruiting
The investigators aim to test the effectiveness of a high maintenance daily dose of buprenorphine (24 mg) for improving outcomes among patients who used fentanyl compared to the standard daily dose (16 mg). The main question it aims to answer is: will patients who are randomly assigned to the high 24 mg maintenance dose, as compared to patients randomly assigned to the standard 16 mg maintenance dose, have improved retention in buprenorphine treatment (primary outcome), improved treatment respo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Brown University, Providence, Rhode Island
Conditions: Opioid Use Disorder
Register for Updates
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT04398628
Recruiting
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/26/2025
Locations: Rhode Island Hospital Hemostasis and Thrombosis Center, Providence, Rhode Island
Conditions: Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Register for Updates
Collaborative Care Model for Perinatal Wellness Support Services - Population-Level Equity-Centered Systems Change
NCT06849869
Recruiting
The collaborative care model (CCM) is a health services intervention that integrates mental health care in primary care settings. The goal of this study is to adapt the CCM to the perinatal care context, including community co-designed adaptations to enhance health equity (COMPASS+). The main objectives of the study are to: 1. Evaluate the effect of COMPASS+ on depression symptom outcomes. Specifically we will evaluate population-level depression symptom trajectories and the prevalence of suici... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Women and Infants Hospital, Providence, Rhode Island
Conditions: Perinatal Mental Health
Register for Updates
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
NCT05806164
Recruiting
The goal of this clinical trial is to compare treatment outcomes between an oral medication (beta agonist) versus onabotulinumtoxinA injections in women with urgency urinary incontinence (UUI). Participants will be randomly selected to receive one of the two treatments. The primary outcome measure will be at 3 months, and women will be followed for a total of 12 months. Based on patient expert input, there are 2 primary outcomes: Treatment satisfaction and urinary symptom severity.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Women & Infants Hospital of Rhode Island, Providence, Rhode Island
Conditions: Urgency Urinary Incontinence
Register for Updates
Improving Social Connectedness Through Digital Health to Enhance Recovery from OUD Among the Justice Involved Population
NCT06896656
Recruiting
People with a history of Opioid Use Disorder and criminal justice involvement are more likely to experience loneliness following release from jail/prison leading to negative outcomes such as treatment dropout and increased substance use. Providing peer recovery support, particularly through a highly accessible, digital health platform, is a potential way to decrease loneliness in this population. The current study seeks to test whether a mobile peer recovery support app, delivered to individuals... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Loneliness, Opioid Use Disorder
Register for Updates
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
NCT05839119
Recruiting
This study is for patients who have bladder cancer that invades into the muscle wall of the bladder. The standard treatment for patients with muscle invasive bladder cancer is to give 4 cycles of chemotherapy with the drugs cisplatin and gemcitabine, then to do an operation to remove the bladder (cystectomy). In this study, the investigators will test participants' bladder cancer to see if their bladder cancer has a receptor for testosterone inside the bladder cancer cells. If it has the testos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Lifespan Cancer Institute, Providence, Rhode Island
Conditions: Urothelial Carcinoma Bladder, Androgen Receptor Positive
Register for Updates
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab for Patients Who Are Disease Free After Completion of Trimodality Treatment for HER-2+ Cancers of Esophagus & Gastroesophageal Junction
NCT05480384
Recruiting
An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who have completed chemoradiation followed by esophagectomy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Lifespan Cancer Institute, Providence, Rhode Island
Conditions: Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer
Register for Updates
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
NCT04933903
Recruiting
This single-arm phase 2 study will enroll patients with resectable and operable stage IB - III non-small cell lung cancer and treat them with pre-operative ipilimumab + nivolumab plus low-dose stereotactic body radiation therapy (SBRT) delivered concurrently. Only patients who proceed to surgery will be evaluable for the primary endpoint. The primary efficacy outcome measurement will be pathologic response (including Major Pathologic Response (MPR), and Complete Pathologic Response (CPR)). Secon... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Non Small Cell Lung Cancer
Register for Updates
Mosunetuzumab with Lenalidomide Augmentation As First-line Therapy for Follicular and Marginal Zone Lymphoma
NCT04792502
Recruiting
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start treatment with four 21-day cycles (C1-4) of mosunetuzumab alone (using step-up dosing during C1), followed by IRA. Patients who achieve CR at IRA will continue with additional 4 cycles (C5-8) of mosunetuzumab. Patients wh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Lifespan Cancer Insitute, Providence, Rhode Island
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma
Register for Updates
A New Clinical Model for the Engagement of Latinx Youth with Suicidal Behavior
NCT06882798
Recruiting
This study will test a model of providing treatment to Latinx/Hispanic youth, who experience suicidal thoughts and behavior, and their caregivers. An affirmative and culturally relevant treatment will be provided to all youth and half of the families will be assigned to the additional support of a community health worker (CHW). Youth symptoms and family engagement to treatment will be followed for nine months. The potential benefit of adding the CHW intervention will be assessed.
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
03/17/2025
Locations: Bradley Hasbro Children's Research Center, Providence, Rhode Island
Conditions: Suicide Ideation, Suicidal Behaviors, Depressive Symptoms
Register for Updates